Paper Details

  1. Home
  2. Paper Details

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Author: AltenRieke, BoxJane, CovarrubiasArturo, DelaetIngrid, DurezPatrick, GenoveseMark C, KeisermanMauro, LegertonClarence William, LeonGustavo, MyslerEduardo, NashPeter, NasonovEvgeny, Simon-CamposJ Abraham, TenaCésar Pacheco, TengJulie, ValenteRobert

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Subcutaneous abatacept is a well-tolerated and efficacious long-term treatment for patients with rheumatoid arthritis and inadequate response to methotrexate.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Assess longterm tolerability, safety, and efficacy of subcutaneous (SC) abatacept (ABA) in methotrexate-refractory patients with rheumatoid arthritis (RA). METHODS: The phase III, multinational Abatacept Comparison of Sub[QU]cutaneous Versus Intravenous in Inadequate Responders to Methot...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3899/jrheum.130112

データ提供：米国国立医学図書館（NLM）

Long-Term Subcutaneous Abatacept for Rheumatoid Arthritis: A Desert Oasis of Hope

In the vast and often challenging landscape of rheumatoid arthritis (RA) research, finding safe and effective long-term treatments is crucial. This study delves into the world of abatacept, a medication used to treat RA, exploring its long-term effects when delivered subcutaneously (under the skin) in patients who didn't respond well to methotrexate, a common RA treatment. The researchers analyzed data from the ACQUIRE trial, a significant research expedition in the RA field, to assess the safety, tolerability, and efficacy of abatacept over an extended period.

A Promising Long-Term Treatment Option

The study found that subcutaneous abatacept was well-tolerated and maintained its effectiveness in controlling RA symptoms over a period of almost 3.5 years. This is a significant finding, as it suggests that subcutaneous abatacept could be a viable long-term treatment option for many patients with RA. The results showed that the majority of patients who completed the initial study continued to take abatacept and experienced sustained improvement in their RA symptoms.

Hope for a More Comfortable Journey

This research offers hope for individuals with RA, providing a potential path to a more comfortable and manageable journey through the challenging desert of RA. The long-term efficacy and tolerability of subcutaneous abatacept are valuable additions to the RA treatment arsenal. This research underscores the importance of continuous research and development in the field of RA, as we strive to discover new ways to alleviate suffering and improve the quality of life for those affected by this debilitating condition.

Dr. Camel's Conclusion

This research offers a glimmer of hope for individuals with RA, providing a potential path to a more comfortable and manageable journey through the challenging desert of RA. The long-term efficacy and tolerability of subcutaneous abatacept are valuable additions to the RA treatment arsenal. This research underscores the importance of continuous research and development in the field of RA, as we strive to discover new ways to alleviate suffering and improve the quality of life for those affected by this debilitating condition.

Date :
  1. Date Completed 2014-12-17
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

24584926

DOI: Digital Object Identifier

10.3899/jrheum.130112

Related Literature

Article Analysis
・Effects of abatacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.